These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 38884266)

  • 1. Crizotinib therapy for congenital embryonal rhabdomyosarcoma associated with an ATIC-ALK gene fusion.
    Akane Y; Yamamoto M; Takebayashi A; Hamada R; Igarashi K; Emori M; Sugita S; Takada K; Hasegawa T; Tsugawa T
    Pediatr Blood Cancer; 2024 Sep; 71(9):e31148. PubMed ID: 38884266
    [No Abstract]   [Full Text] [Related]  

  • 2. The Presence of ALK Alterations and Clinical Relevance of Crizotinib Treatment in Pediatric Solid Tumors.
    Felkai L; Bánusz R; Kovalszky I; Sápi Z; Garami M; Papp G; Karászi K; Varga E; Csóka M
    Pathol Oncol Res; 2019 Jan; 25(1):217-224. PubMed ID: 29081033
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Identification of a novel ALK inhibitor-sensitive PRKCE-ALK gene fusion in lung adenocarcinoma.
    Wang L; Li L; Zhou X; Zhang D
    Lung Cancer; 2024 May; 191():107797. PubMed ID: 38669726
    [No Abstract]   [Full Text] [Related]  

  • 4. A Novel Intergenic Region between CENPA and DPYSL5-ALK Exon 20 Fusion Variant Responding to Crizotinib Treatment in a Patient with Lung Adenocarcinoma.
    Fei X; Zhu L; Zhou H; Qi C; Wang C
    J Thorac Oncol; 2019 Sep; 14(9):e191-e193. PubMed ID: 31445731
    [No Abstract]   [Full Text] [Related]  

  • 5. A novel SOS1-ALK fusion variant in a patient with metastatic lung adenocarcinoma and a remarkable response to crizotinib.
    Chen HF; Wang WX; Xu CW; Huang LC; Li XF; Lan G; Zhai ZQ; Zhu YC; Du KQ; Lei L; Fang MY
    Lung Cancer; 2020 Apr; 142():59-62. PubMed ID: 32114282
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The clinical responses of TNIP2-ALK fusion variants to crizotinib in ALK-rearranged lung adenocarcinoma.
    Feng T; Chen Z; Gu J; Wang Y; Zhang J; Min L
    Lung Cancer; 2019 Nov; 137():19-22. PubMed ID: 31521978
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Coexistence of a novel RGS18 downstream intergenic region ALK fusion and a THUMPD2-ALK fusion in a lung adenocarcinoma patient and response to crizotinib.
    Wang YL; Wu ZZ; Zhang HR; Chen DS; Zhao X
    Lung Cancer; 2021 Apr; 154():216-218. PubMed ID: 33637344
    [No Abstract]   [Full Text] [Related]  

  • 8. ALK inhibitors in the treatment of advanced NSCLC.
    Gridelli C; Peters S; Sgambato A; Casaluce F; Adjei AA; Ciardiello F
    Cancer Treat Rev; 2014 Mar; 40(2):300-6. PubMed ID: 23931927
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Next-generation Sequencing Identified a Novel WDPCP-ALK Fusion Sensitive to Crizotinib in Lung Adenocarcinoma.
    He Z; Wu X; Ma S; Zhang C; Zhang Z; Wang S; Yu S; Wang Q
    Clin Lung Cancer; 2019 Sep; 20(5):e548-e551. PubMed ID: 31281052
    [No Abstract]   [Full Text] [Related]  

  • 10. Novel PNPT1-ALK fusion variant exerted significant benefit to crizotinib in NSCLC.
    Jin L; Wang Y; Li S; Chen D; Zhao X
    Lung Cancer; 2020 Aug; 146():382-384. PubMed ID: 32540202
    [No Abstract]   [Full Text] [Related]  

  • 11. New insights into anaplastic lymphoma kinase-positive nonsmall cell lung cancer.
    Dubey AP; Pathi N; Viswanath S; Rathore A; Pathak A; Sud R
    Indian J Cancer; 2017; 54(1):203-208. PubMed ID: 29199691
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A Novel Linc00308/D21S2088E Intergenic Region ALK Fusion and Its Enduring Clinical Responses to Crizotinib.
    Zhang J; Zou C; Zhou C; Luo Y; He Q; Sun Y; Zhou J; Ke Z
    J Thorac Oncol; 2020 Jun; 15(6):1073-1077. PubMed ID: 32217130
    [No Abstract]   [Full Text] [Related]  

  • 13. Clinicopathological features and resistance mechanisms in HIP1-ALK-rearranged lung cancer: A multicenter study.
    Kang J; Deng QM; Peng KC; Li P; Zhu BT; Wang P; Chu XP; Zhong WZ; Chen HJ; Wang WX; Chen HF; Rao CZ; Xu CW; Yang JJ
    Genes Chromosomes Cancer; 2022 Apr; 61(4):177-186. PubMed ID: 34687488
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A novel HIP1-ALK fusion variant in lung adenocarcinoma showing resistance to Crizotinib.
    Li M; Tang Q; Chen S; Wang Y
    Lung Cancer; 2021 Jan; 151():98-100. PubMed ID: 33280926
    [No Abstract]   [Full Text] [Related]  

  • 15. A novel
    Pan X; Zhong A; Xing Y; Li X; Du H; Shi M
    J Int Med Res; 2021 Sep; 49(9):3000605211044652. PubMed ID: 34590916
    [TBL] [Abstract][Full Text] [Related]  

  • 16. CUX1-ALK, a Novel ALK Rearrangement That Responds to Crizotinib in Non-Small Cell Lung Cancer.
    Zhang M; Wang Q; Ding Y; Wang G; Chu Y; He X; Wu X; Shao YW; Lu K
    J Thorac Oncol; 2018 Nov; 13(11):1792-1797. PubMed ID: 30010043
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A new human lung adenocarcinoma cell line harboring the EML4-ALK fusion gene.
    Isozaki H; Yasugi M; Takigawa N; Hotta K; Ichihara E; Taniguchi A; Toyooka S; Hashida S; Sendo T; Tanimoto M; Kiura K
    Jpn J Clin Oncol; 2014 Oct; 44(10):963-8. PubMed ID: 25170107
    [TBL] [Abstract][Full Text] [Related]  

  • 18. ALK-rearrangement in non-small-cell lung cancer (NSCLC).
    Du X; Shao Y; Qin HF; Tai YH; Gao HJ
    Thorac Cancer; 2018 Apr; 9(4):423-430. PubMed ID: 29488330
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Anaplastic lymphoma kinase-positive anaplastic large cell lymphoma with the variant RNF213-, ATIC- and TPM3-ALK fusions is characterized by copy number gain of the rearranged ALK gene.
    van der Krogt JA; Bempt MV; Ferreiro JF; Mentens N; Jacobs K; Pluys U; Doms K; Geerdens E; Uyttebroeck A; Pierre P; Michaux L; Devos T; Vandenberghe P; Tousseyn T; Cools J; Wlodarska I
    Haematologica; 2017 Sep; 102(9):1605-1616. PubMed ID: 28659337
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Successful Treatment with Crizotinib to Overcome Drug Resistance Possibly Due to Mesenchymal-epithelial Transition Amplification in a Lung Cancer Patient with the Echinoderm Microtubule-associated Protein-like 4-anaplastic Lymphoma Kinase Fusion Gene.
    Shiraishi T; Yamasaki K; Kidogawa M; Shingu T; Ujimiya F; Jotatsu T; Matsumoto S; Izumi H; Nishida C; Goto K; Yatera K
    Intern Med; 2023 Nov; 62(21):3215-3221. PubMed ID: 36927974
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.